Gut microbiome a potential biomarker for nivolumab efficacy in advanced gastric cancer

The gut microbiome potentially could serve as a biomarker to predict the efficacy of nivolumab among patients with advanced gastric cancer, according to results of the DELIVER trial presented at Gastrointestinal Cancers Symposium.Gastric cancer-specific gut microbiome additionally appeared to predict immune checkpoint inhibitor response, researchers noted.“Previous research demonstrated a survival benefit of nivolumab [Opdivo, Bristol Myers Squibb] monotherapy among previously treated patients with advanced gastric cancer,” Yu Sunakawa, MD, PhD, associate professor in theRead More

Share on facebook
Share on twitter
Share on linkedin